Table 2.
Baseline and procedural characteristics after matching
| Total study cohort | FFR-guided treatment arm | Angiography-guided treatment arm | SMD in % | |
|---|---|---|---|---|
| (p value) | ||||
| N | 1258 | 629 | 629 | – |
| Demographics | ||||
| Male | 856 (68.0) | 428 (68.0) | 428 (68.0) | 0 (> 0.9999) |
| Mean age | 69.0 (11.4) | 69.0 (11.4) | 69.0 (11.4) | 0 (> 0.9999) |
| Age < 65 years | 430 (34.2) | 215 (34.2) | 215 (34.2) | 0 (> 0.9999) |
| Age 65 ≤ 75 years | 354 (28.1) | 176 (28.0) | 178 (28.3) | 0.71 (0.9500) |
| Age ≥ 75 years | 474 (37.7) | 238 (37.8) | 236 (37.5) | 0.66 (0.9536) |
| Comorbidities/risk factors | ||||
| Known CAD | 691 (54.9) | 347 (55.2) | 344 (54.7) | 0.96 (0.9300) |
| Known heart failure | 221 (17.6) | 112 (17.8) | 109 (17.3) | 1.25 (0.8822) |
| Renal failure | 20 (1.6) | 11 (1.7) | 9 (1.4) | 2.54 (0.8217) |
| Diabetes mellitus | 469 (37.3) | 220 (35.0) | 249 (39.6) | 9.55 (0.1026) |
| Arterial hypertension | 1015 (80.7) | 505 (80.3) | 510 (81.1) | 2.01 (0.7751) |
| Obesity | 280 (22.3) | 142 (22.6) | 138 (21.9) | 1.53 (0.8389) |
| Dyslipidemia | 824 (65.5) | 414 (65.8) | 410 (65.2) | 1.34 (0.8588) |
| Medical therapy | ||||
| Antiplatelets | 374 (29.7) | 179 (28.5) | 195 (31.0) | 5.57 (0.3548) |
| Beta blockers | 670 (53.3) | 336 (53.4) | 334 (53.1) | 0.64 (0.9549) |
| ACE inhibitors/ARB | 434 (34.5) | 213 (33.9) | 221 (35.1) | 2.68 (0.6780) |
| Statins | 627 (49.8) | 309 (49.1) | 318 (50.6) | 2.86 (0.6519) |
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, CAD coronary artery disease, FFR fractional flow reserve, SMD standard mean difference